Massimo Procopio

2.7k total citations
83 papers, 1.9k citations indexed

About

Massimo Procopio is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Physiology. According to data from OpenAlex, Massimo Procopio has authored 83 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Endocrinology, Diabetes and Metabolism, 20 papers in Molecular Biology and 19 papers in Physiology. Recurrent topics in Massimo Procopio's work include Growth Hormone and Insulin-like Growth Factors (42 papers), Pituitary Gland Disorders and Treatments (18 papers) and Metabolism, Diabetes, and Cancer (16 papers). Massimo Procopio is often cited by papers focused on Growth Hormone and Insulin-like Growth Factors (42 papers), Pituitary Gland Disorders and Treatments (18 papers) and Metabolism, Diabetes, and Cancer (16 papers). Massimo Procopio collaborates with scholars based in Italy, Belarus and Russia. Massimo Procopio's co-authors include Ezio Ghigo, F. Camanni, Mauro Maccario, Giorgio Borretta, Silvia Grottoli, Emanuela Arvat, Enrico Mazza, S. E. Oleandri, J. Bellone and Massimo Terzolo and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, The American Journal of Cardiology and International Journal of Obesity.

In The Last Decade

Massimo Procopio

83 papers receiving 1.9k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Massimo Procopio 1.2k 463 414 393 310 83 1.9k
Helene Nørrelund 1.2k 1.0× 754 1.6× 188 0.5× 443 1.1× 276 0.9× 67 2.0k
Akio Kuroda 453 0.4× 281 0.6× 409 1.0× 443 1.1× 48 0.2× 65 1.4k
Michael M. Swarbrick 543 0.4× 1.8k 4.0× 448 1.1× 708 1.8× 236 0.8× 41 2.9k
Steven C. Elbein 1.0k 0.8× 859 1.9× 867 2.1× 1.2k 3.1× 161 0.5× 63 3.1k
Agnieszka Nikołajuk 325 0.3× 768 1.7× 204 0.5× 630 1.6× 241 0.8× 89 2.1k
Marie S. Thearle 316 0.3× 971 2.1× 188 0.5× 413 1.1× 258 0.8× 45 1.8k
Ralf Nass 655 0.5× 655 1.4× 158 0.4× 207 0.5× 585 1.9× 45 1.5k
Hideo Manaka 1.1k 0.9× 359 0.8× 370 0.9× 637 1.6× 125 0.4× 55 2.1k
Mark E. Cleasby 283 0.2× 1.0k 2.2× 242 0.6× 828 2.1× 86 0.3× 33 2.1k
Ilkka Vauhkonen 950 0.8× 464 1.0× 507 1.2× 453 1.2× 159 0.5× 42 2.4k

Countries citing papers authored by Massimo Procopio

Since Specialization
Citations

This map shows the geographic impact of Massimo Procopio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Massimo Procopio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Massimo Procopio more than expected).

Fields of papers citing papers by Massimo Procopio

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Massimo Procopio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Massimo Procopio. The network helps show where Massimo Procopio may publish in the future.

Co-authorship network of co-authors of Massimo Procopio

This figure shows the co-authorship network connecting the top 25 collaborators of Massimo Procopio. A scholar is included among the top collaborators of Massimo Procopio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Massimo Procopio. Massimo Procopio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Settanni, Fabio, et al.. (2024). Decreased trabecular bone score in patients affected by Fabry disease. Journal of Endocrinological Investigation. 48(1). 121–130. 1 indexed citations
2.
Bioletto, Fabio, Alessandro Maria Berton, Nunzia Prencipe, et al.. (2024). Mild Hyponatremia Is Not Associated With Degradation of Trabecular Bone Microarchitecture Despite Bone Mass Loss. The Journal of Clinical Endocrinology & Metabolism. 110(3). e774–e782. 5 indexed citations
3.
Ghigo, Ezio, et al.. (2024). Normocalcemic primary hyperparathyroidism is not associated with cardiometabolic alterations. Endocrine. 86(3). 1140–1147. 1 indexed citations
4.
Bioletto, Fabio, Alessandro Maria Berton, Nunzia Prencipe, et al.. (2024). Mild hyponatremia is not associated with degradation of trabecular bone microarchitecture despite bone mass loss. Endocrine Abstracts. 1 indexed citations
5.
Bioletto, Fabio, Mirko Parasiliti‐Caprino, Vincenzo Cappiello, et al.. (2023). Bone safety of dual-release hydrocortisone in patients with autoimmune primary adrenal insufficiency. Frontiers in Endocrinology. 14. 1234237–1234237. 4 indexed citations
6.
Bioletto, Fabio, Nunzia Prencipe, Alessandro Maria Berton, et al.. (2022). Trabecular Bone Score as an Index of Bone Fragility in Patients with Acromegaly: A Systematic Review and Meta-Analysis. Neuroendocrinology. 113(4). 395–405. 20 indexed citations
7.
Motta, Giovanna, Paolo Riccardo Brustio, Chiara Manieri, et al.. (2020). Fracture risk assessment in an Italian group of transgender women after gender-confirming surgery. Journal of Bone and Mineral Metabolism. 38(6). 885–893. 13 indexed citations
8.
Ribaldone, Davide Giuseppe, Massimo Procopio, Rinaldo Pellicano, et al.. (2020). Predictors of risk of fracture in inflammatory bowel diseases: a prospective study using FRAX score. PubMed. 66(2). 106–112. 3 indexed citations
9.
10.
Procopio, Massimo. (2017). Il Trattamento tributario dei costi relativi al sostegno delle società benefit. 88(1). 81–106. 3 indexed citations
11.
Bo, Simona, Valentina Ponzo, Andrea Evangelista, et al.. (2017). Effects of 6 months of resveratrol versus placebo on pentraxin 3 in patients with type 2 diabetes mellitus: a double-blind randomized controlled trial. Acta Diabetologica. 54(5). 499–507. 22 indexed citations
12.
Bo, Simona, Valentina Ponzo, Giovannino Ciccone, et al.. (2016). Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial. Pharmacological Research. 111. 896–905. 126 indexed citations
13.
Procopio, Massimo, et al.. (2013). Cardiovascular risk and metabolic syndrome in primary hyperparathyroidism and their correlation to different clinical forms. Endocrine. 47(2). 581–589. 34 indexed citations
14.
Procopio, Massimo, et al.. (2012). Metabolic disorders and hypertension in mild primary hyperparathyroidism. Bone. 50. S172–S172. 1 indexed citations
15.
Procopio, Massimo, et al.. (2005). The hormonal environment in utero as a potential aetiological agent for schizophrenia. European Archives of Psychiatry and Clinical Neuroscience. 256(2). 77–81. 22 indexed citations
16.
Maccario, Mauro, Enrico Mazza, J. Ramunni, et al.. (1999). Relationships between dehydroepiandrosterone‐sulphate and anthropometric, metabolic and hormonal variables in a large cohort of obese women. Clinical Endocrinology. 50(5). 595–600. 46 indexed citations
17.
Razzore, Paola, Massimo Procopio, S. E. Oleandri, et al.. (1996). Effects of glucose load and/or arginine on insulin and growth hormone secretion in hyperprolactinemia and obesity. European Journal of Endocrinology. 135(2). 205–210. 15 indexed citations
18.
Procopio, Massimo, Sandro Loche, Marco Cappa, et al.. (1994). Interaction of free fatty acids and arginine on growth hormone secretion in man. Metabolism. 43(2). 223–226. 37 indexed citations
19.
Ghigo, Ezio, Enrico Mazza, J. Bellone, et al.. (1990). Neuroactive Drugs in Growth Disorders. Acta Paediatrica. 79(s367). 33–37. 1 indexed citations
20.
Ghigo, Ezio, E. Imperiale, Enrico Mazza, et al.. (1989). Cholinergic Enhancement by Pyridostigmine Potentiates Spontaneous Diurnal but not Nocturnal Growth Hormone Secretion in Short Children. Neuroendocrinology. 49(2). 134–137. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Helene Nørrelund Breakdown of academic impact, for papers by Akio Kuroda Breakdown of academic impact, for papers by Michael M. Swarbrick Breakdown of academic impact, for papers by Steven C. Elbein Breakdown of academic impact, for papers by Agnieszka Nikołajuk Breakdown of academic impact, for papers by Marie S. Thearle Breakdown of academic impact, for papers by Ralf Nass Breakdown of academic impact, for papers by Hideo Manaka Breakdown of academic impact, for papers by Mark E. Cleasby Breakdown of academic impact, for papers by Ilkka Vauhkonen
Rankless by CCL
2026